Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmet Dogan

Showing results (341-350 of 371) with videos related to

Pageof 38
Sort By:
Research Square|November 24, 2025
Interpretable Multiple Instance Learning for Hematologic Diagnosis from Peripheral Blood SmearsSiddharth Singi, Shenghuan Sun, Zhanghan Yin, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingJens G Lohr, Petar Stojanov, Michael S Lawrence, et al.
Communications Medicine|April 14, 2026
Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smearsSiddharth Singi, Shenghuan Sun, Zhanghan Yin, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
The American Journal of Surgical Pathology|December 2, 2017
Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell LymphomaMaria C Ferrufino-Schmidt, L Jeffrey Medeiros, Hui Liu, et al.
Haematologica|March 7, 2024
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignanciesMelissa Krystel-Whittemore, Kseniya Petrova-Drus, Ryan N Ptashkin, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 38

Showing results (341-350 of 371) with videos related to

Sort By:
Pageof 38
Research Square|November 24, 2025
Interpretable Multiple Instance Learning for Hematologic Diagnosis from Peripheral Blood SmearsSiddharth Singi, Shenghuan Sun, Zhanghan Yin, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingJens G Lohr, Petar Stojanov, Michael S Lawrence, et al.
Communications Medicine|April 14, 2026
Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smearsSiddharth Singi, Shenghuan Sun, Zhanghan Yin, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
The American Journal of Surgical Pathology|December 2, 2017
Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell LymphomaMaria C Ferrufino-Schmidt, L Jeffrey Medeiros, Hui Liu, et al.
Haematologica|March 7, 2024
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignanciesMelissa Krystel-Whittemore, Kseniya Petrova-Drus, Ryan N Ptashkin, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 38